GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Total Liabilities

Kamada (Kamada) Total Liabilities : $96.7 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Kamada Total Liabilities?

Kamada's Total Liabilities for the quarter that ended in Mar. 2024 was $96.7 Mil.

Kamada's quarterly Total Liabilities increased from Sep. 2023 ($98.67 Mil) to Dec. 2023 ($110.89 Mil) but then declined from Dec. 2023 ($110.89 Mil) to Mar. 2024 ($96.66 Mil).

Kamada's annual Total Liabilities increased from Dec. 2021 ($141.84 Mil) to Dec. 2022 ($146.36 Mil) but then declined from Dec. 2022 ($146.36 Mil) to Dec. 2023 ($110.89 Mil).


Kamada Total Liabilities Historical Data

The historical data trend for Kamada's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Total Liabilities Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.48 32.03 141.84 146.36 110.89

Kamada Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 141.99 137.64 98.67 110.89 96.66

Kamada Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kamada's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=49.593+(7.438+53.234
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.621)
=110.9

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=354.907-244.021
=110.9

Kamada's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=37.175+(7.278+51.602
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.609)
=96.7

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=343.174-246.51
=96.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kamada Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kamada's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada (Kamada) Business Description

Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada (Kamada) Headlines

From GuruFocus

Kamada Awarded $22 Million Extension of Canadian Supply Tender

By Value_Insider Value_Insider 10-19-2022